Last $2.30 USD
Change Today 0.00 / 0.00%
Volume 1.3M
ATRS On Other Exchanges
As of 5:20 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/15/14 - $5.01
52 Week Low
09/30/14 - $1.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Medi-Jet technology to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle. Its transdermal products comprise Gelnique3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company is also developing OTREXUP for the treatment poly-articular-course juvenile RA and psoriasis; Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency; Vibex auto injectors; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Daewoong Pharmaceuticals; Meda Pharmaceuticals; Pfizer Inc; Population Council; and LEO Pharma. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

60 Employees
Last Reported Date: 03/13/14
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2013.

antares pharma inc (ATRS) Key Developments

Antares Pharma, Inc. Appoints James E. Fickenscher to the Position of Senior Vice President and Chief Financial Officer

Antares Pharma Inc. announced the appointment of James E. Fickenscher to the position of Senior Vice President and Chief Financial Officer. Mr. Fickenscher has a diversified corporate background including more than 25 years of experience in the pharmaceutical industry. Most recently, Mr. Fickenscher served as Chief Financial Officer of Auxilium Pharmaceuticals Inc. from May 2005 until August 2014.

Antares Pharma Inc. Reports Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014

Antares Pharma Inc. reported unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company’s total revenues were $6.6 million and $5.5 million for the three months ended September 30, 2014 and 2013, respectively, an increase of 19%. Operating loss was $7.2 million against $6.4 million a year ago. Net loss was $7.2 million or $0.05 per basic and diluted share against $6.4 million or $0.05 per basic and diluted share a year ago. For the nine months, the company’s total revenue was $18.1 million compared to $15.9 million in the first nine months of 2013, an increase of 14%. Operating loss was $25.1 million against $14.9 million a year ago. Net loss was $25.1 million or $0.19 per basic and diluted share against $14.9 million or $0.12 per basic and diluted share a year ago.

Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot(R) Study Evaluating Testosterone-Deficient Adult Males

Antares Pharma Inc. announced that the last patient has been enrolled in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot(R) Testosterone (QS T) administered subcutaneously once each week to testosterone-deficient adult males. Patients enrolled in this study had a documented diagnosis of hypogonadism or testosterone deficiency defined as having testosterone levels below 300 ng/dL. The study includes a screening phase, a treatment titration and efficacy phase and an extended treatment phase. Approximately 150 patients are enrolled in this study. Patients meeting all eligibility criteria were assigned to receive a starting dose of QS T once weekly for six weeks. Adjustments to dose could be made at week 7 based upon the week 6 pre-dose blood level. The efficacy of QS T and dose adjustment to regulate testosterone levels will be evaluated after 12 weeks of treatment. Upon completion of this phase, patients may remain on their optimized QS T dose and will be followed for an additional 40 weeks. Approximately 100 patients will be needed to complete collection of 26 weeks of safety data, and approximately 50 patients will be needed to complete collection of 52 weeks of safety data.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $2.30 USD 0.00

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $2.61 USD +0.02
Cerus Corp $4.29 USD +0.04
Pluristem Therapeutics Inc $2.58 USD +0.03
SurModics Inc $21.43 USD -0.32
Uroplasty Inc $2.45 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.2x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at